◆英語タイトル:Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8010771
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月20日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Aptevo Therapeutics Inc (APVO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc is a biotech company that develops and commercializes oncology and hematology therapeutics. The company’s marketed products comprise WinRho SDF, a Rho(D) immune globulin intravenous product indicated for chronic or acute immune thrombocytopenia; Ixinity, a medicine used to replace clotting factor IX that is missing in adults and children with hemophilia B; HepaGam B, an intravenous immune globulin indicated for Hepatitis B; and Varizig, a hyperimmune product that is developed to treat the Varicella zoster virus, which causes the viral infection known as chickenpox. It develops immuno-oncology candidates based on its proprietary Adaptir platform. Aptevo pipeline products include oncology candidates, such as TRU-016, MOR209, APVO425, ES210, and additional RTCC assets. The company also develops other candidates for autoimmune, inflammation and infectious diseases. It has operations in the US and the UK. Aptevo is headquartered in Seattle, Washington, the US.
Aptevo Therapeutics Inc Key Recent Developments
Nov 09,2017: Aptevo Therapeutics Reports Third Quarter 2017 Financial Results
Oct 02,2017: Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit
Aug 29,2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies
Aug 10,2017: Aptevo Therapeutics Reports Second Quarter 2017 Financial Results
May 12,2017: Aptevo Therapeutics Reports First Quarter 2017 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Aptevo Therapeutics Inc – Key Facts 6
Aptevo Therapeutics Inc – Key Employees 7
Aptevo Therapeutics Inc – Major Products and Services 8
Aptevo Therapeutics Inc – History 9
Aptevo Therapeutics Inc – Company Statement 10
Aptevo Therapeutics Inc – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Aptevo Therapeutics Inc – Business Description 13
R&D Overview 13
Aptevo Therapeutics Inc – SWOT Analysis 14
SWOT Analysis – Overview 14
Aptevo Therapeutics Inc – Strengths 14
Aptevo Therapeutics Inc – Weaknesses 15
Aptevo Therapeutics Inc – Opportunities 16
Aptevo Therapeutics Inc – Threats 17
Aptevo Therapeutics Inc – Key Competitors 18
Section 3 – Company Financial Ratios 19
Financial Ratios – Capital Market Ratios 19
Financial Ratios – Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios – Interim Ratios 23
Financial Ratios – Ratio Charts 24
Section 4 – Company’s Lifesciences Financial Deals and Alliances 25
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
Aptevo Therapeutics Inc, Recent Deals Summary 27
Section 5 – Company’s Recent Developments 28
Nov 09, 2017: Aptevo Therapeutics Reports Third Quarter 2017 Financial Results 28
Oct 02, 2017: Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit 30
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 32
Aug 10, 2017: Aptevo Therapeutics Reports Second Quarter 2017 Financial Results 33
May 12, 2017: Aptevo Therapeutics Reports First Quarter 2017 Financial Results 34
May 05, 2017: Aptevo Therapeutics Presents Detailed Overview of its Adaptir Protein Therapeutic Platform at the 13th Annual Pegs Summit 36
Mar 31, 2017: Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update 37
Mar 14, 2017: Aptevo Therapeutics Expands Bispecific Antibody Portfolio 39
Mar 14, 2017: Aptevo Therapeutics Expands Bispecific Antibody Portfolio 40
Jan 13, 2017: Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions 41
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46
List of Tables
Aptevo Therapeutics Inc, Key Facts 6
Aptevo Therapeutics Inc, Key Employees 7
Aptevo Therapeutics Inc, Major Products and Services 8
Aptevo Therapeutics Inc, History 9
Aptevo Therapeutics Inc, Other Locations 12
Aptevo Therapeutics Inc, Subsidiaries 12
Aptevo Therapeutics Inc, Key Competitors 18
Aptevo Therapeutics Inc, Ratios based on current share price 19
Aptevo Therapeutics Inc, Annual Ratios 20
Aptevo Therapeutics Inc, Annual Ratios (Cont...1) 21
Aptevo Therapeutics Inc, Interim Ratios 23
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
Aptevo Therapeutics Inc, Recent Deals Summary 27
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45